The BIM protein can activate the programmed cell death also known as the apoptotic pathway in cells. BIM deletion has been detected in 12.8% of the Asian population but is very rarely observed in the Caucasian population. All NSCLC patients treated with any therapy, targeted or chemotherapeutic, ultimately fail their therapy but at varying times. …
Acute lymphoblastic leukemia (ALL) is the most common cancer of childhood. This disease hinders the development of healthy blood cells while cancer cells proliferate. Currently, children with ALL receive chemotherapy for two to three years, exposing them to significant side effects including changes in normal development and future fertility. As a way to avoid these adverse effects, investigators have been researching how to supercharge the body’s innate cancer-fighting ability — a technique called immunotherapy…
Acute lymphoblastic leukemia (ALL) is the most common cancer of childhood. This disease hinders the development of healthy blood cells while cancer cells proliferate. Currently, children with ALL receive chemotherapy for two to three years, exposing them to significant side effects including changes in normal development and future fertility. …
The criteria — developed in Edinburgh — will help to select which girls should be offered the opportunity to freeze some tissue from their ovaries for use in the future. Doctors are optimistic that the frozen tissue could one day help young cancer survivors to have children of their own…
“There is a window of opportunity in the year after initial therapy to take an aggressive approach to spotting recurrences and intensively addressing them while they are still highly treatable,” says Joseph Califano, M.D., professor of Otolaryngology — Head and Neck Surgery, member of the Johns Hopkins Kimmel Cancer Center, and medical director of the Milton J. Dance Jr. Head and Neck Center at the Greater Baltimore Medical Center. “Until now, there has been no reliable biological way to identify which patients are at higher risk for recurrence, so these tests should greatly help do so,” he adds. …
With a new technique, researchers at the University of Pennsylvania have established a new strategy to help surgeons see the entire tumor in the patient, increasing the likelihood of a positive outcome. This approach relies on an injectable dye that accumulates in cancerous tissues much more so than normal tissues…
The results build upon earlier findings reported in November 2013, showing that EA can decrease the joint pain reported by roughly 50 percent of breast cancer patients taking AIs — the most-commonly prescribed medications to prevent disease recurrence among post-menopausal women with early-stage, hormone receptor positive breast cancer. Despite their efficacy, the joint pain associated with the use of AIs often leads to fatigue, anxiety, depression, and sleep disturbances for these patients, which researchers suggest may cause premature discontinuation of the drug. …
The findings come from a study that looked at squamocolumnar junction cells, or SCJ cells. These cells reside in the cervical canal and have been implicated as the origins of cervical cancer…
Until now, the strategies for treating this tumor were aimed at attacking the tumor cells and had little success. The latest studies indicate that trying to destroy what surrounds the tumor is possibly a better strategy…
Trebananib (formally known as AMG 386; Amgen) is a first-in-class peptide-Fc fusion protein (or peptibody) that targets angiogenesis (the growth of new blood vessels into cancerous tumors) by inhibiting the binding of both angiopoietin 1 and 2 to the Tie2 receptor. This is very different mechanism of action than other agents that also effect angiogenesis by inhibiting vascular endothelial growth factor (VEGF) such as bevacizumab (Avastin; Genentech). Trebananib does not increase the risks of hypertension (high blood pressure) and bowel perforation like bevaciuzmab, but still has a similar impact on tumor shrinkage and delaying cancer progression…